Eric Schadt, PhD

Eric Schadt, PhD, is Director of the Icahn Institute for Genomics and Multiscale Biology, Chair of the Department of Genetics and Genomics Sciences, and the Jean C. and James W. Crystal Professor of Genomics at the Icahn School of Medicine at Mount Sinai.

Dr. Schadt is an expert on the generation and integration of very large-scale sequence variation, molecular profiling and clinical data in disease populations for constructing molecular networks that define disease states and link molecular biology to physiology. He is known for calling for a shift in molecular biology toward a network-oriented view of living systems to complement the reductionist, single-gene approaches that currently dominate biology in order to more accurately model the complexity of biological systems. Dr. Schadt’s research has provided novel insights into what it is needed to master diverse, large-scale data collected on normal and disease populations in order to elucidate the complexity of disease and make more informed decisions in the drug discovery arena. He has published more than 200 peer-reviewed papers in leading scientific journals, and contributed to a number of discoveries relating to the genetic basis of common human diseases such as diabetes, obesity, and Alzheimer’s disease.

Dr. Schadt is also a founding member of Sage Bionetworks, an open-access genomics initiative designed to build and support databases and an accessible platform for creating innovative disease models. Prior to joining Mount Sinai in 2011, he was Chief Scientific Officer at Pacific Biosciences, the next-generation sequencing technology provider. Previously, Dr. Schadt was Executive Scientific Director of Genetics at Rosetta Inpharmatics, a subsidiary of Merck & Co., Inc. in Seattle, and before Rosetta, Dr. Schadt was a Senior Research Scientist at Roche Bioscience. He received his BA in applied mathematics and computer science from California Polytechnic State University, his MA in pure mathematics from University of California, Davis, and his PhD in bio-mathematics from University of California, Los Angeles (requiring PhD candidacy in molecular biology and mathematics).

Stuart A. Scott, PhD

Stuart A. Scott, PhD, is an Assistant Professor in the Department of Genetics and Genomics Sciences at the Icahn School of Medicine at Mount Sinai and is an ABMM-certified Associate Director of the Mount Sinai Genetic Testing Laboratory. In addition to clinical laboratory diagnostics, his research interests have focused on translational molecular biology, particularly in the areas of pharmacogenomics, epigenomics, and epigenetics. Dr. Scott was a Mount Sinai ‘Conduits’ KL2 Faculty Scholar from 2011-2013, with a research project directed at identifying additional genetic variants implicated in antipsychotic response variability. These studies are being expanded upon for his 2013 NIGMS Translational Scholar Career Award in Pharmacogenomics and Personalized Medicine (K23), with the overall goal of identifying novel pharmacogenomic variants and increasing the utility of genetic testing for personalized drug therapy. Consistent with his clinical training and research interests, he is a member of the Clinical Pharmacogenomics Implementation Consortium (CPC) as well as other international pharmacogenomic research consortia, and is a co-investigator of the pharmacogenomic implementation projects initiated by the Institute for Personalized Medicine (IPM) at Mount Sinai. Other honors include the 2011 William Bowes Jr. Award in Medical Genetics, sponsored by the Center for Personalized Medicine at Harvard Medical School, and the 2012 Dr. Harold and Golden Lampert Research Award, sponsored by the Icahn School of Medicine at Mount Sinai.
which is the first major text stage of the research pipeline to build on the Austin is applying his experiences in nearly every bottlenecks exist in the translational pipeline. across a wide range of human diseases and will enhance the development, testing and Division of Pre-Clinical Innovation since the Health Thomas R. Insel, MD

Christopher P. Austin, MD, as director of the National Center for announced the appointment of Christopher P. Austin, MD, as director of the National Center for Advancing Translational Sciences (NCATS). Austin succeeded former acting director of NCATS and current director of the National Institute of Mental Health Thomas R. Insel, MD. Frederick, who served as director of the NCATS Division of Pre-Clinical Innovation since the creation of the Center in November 2012, announced his intention to leave NCATS in its mission to catalyze the generation of innovative methods and technologies that can advance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. Currently, many costly, time-consuming bottlenecks exist in the translational pipeline, which is impeding its progress in nearly every stage of the research pipeline to build on the discoveries and to get them into patients—efforts that are yielding promising new approaches to developing novel medications for these disorders.

Dr. Austin’s appointment as director of NCATS is the latest in a series of significant leadership changes at the National Institutes of Health (NIH). The NIH recently announced the appointment of Bruce A. Beutler, MD, as director of the National Institute of Allergy and Infectious Diseases. In addition, the NIH recently named Francis S. Collins, MD, PhD, as director of the National Human Genome Research Institute (NHGRI). The NIH also recently announced the appointment of Gary L. Goldin, MD, as director of the National Institute on Aging.

Dr. Austin is a native of Pittsburgh, Pennsylvania, and received his MD from the University of Pittsburgh School of Medicine. He completed his internship and residency at the University of Pennsylvania Health System, where he served as chief resident in internal medicine. Following his residency, Dr. Austin completed a fellowship in endocrinology, diabetes, and metabolism at Johns Hopkins University School of Medicine. He then completed a fellowship in endocrinology, diabetes, and metabolism at the University of California, San Francisco, where he served as chief fellow in endocrinology, diabetes, and metabolism.

Dr. Austin then joined the faculty of the University of California, San Francisco, where he has served as associate professor of medicine, associate professor of pediatrics, and associate professor of pharmacology. Dr. Austin has served as the director of the Center for Translational Medicine and Innovation, and as the director of the Center for the Commercialization of Translational Medicine. Dr. Austin has served on the editorial board of the journal Diabetes, and he has served as an associate editor for the journal Diabetes Metabolism Research and Reviews. Dr. Austin has also served as a member of the National Institutes of Health (NIH) External Advisory Board for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and as a member of the NIH Clinical Center Advisory Board.

Dr. Austin has received numerous awards for his contributions to translational medicine, including the NIH Director’s Early Independence Award, the NIH Director’s New Innovator Award, the NIH Director’s Vision Award, and the NIH Director’s Early Independence Award. Dr. Austin has also received the NIH Director’s Award for Excellence in Public Health, the NIH Director’s Early Independence Award, and the NIH Director’s Vision Award. Dr. Austin has also been named a Fellow of the American College of Physicians, and he has served on the editorial board of the journal Circulation Research.